Intriguingly, TFDP3 confers chemoresistance in minimal residual disease within childhood T-cell acute lymphoblastic leukemia, and downregulation of TFDP3 by RNA interference sensitizes cancer cells to combinational chemotherapy. This evidence concerns the gene TFDP3 and cancer.